Sentinel Node Biopsy: Reasons for Failure

Oncology NEWS InternationalOncology NEWS International Vol 9 No 2
Volume 9
Issue 2

GREENVILLE, NC-Patient age and surgeon experience appear to play the biggest role in failure of sentinel lymph node biopsy for detection of breast cancer, according to a large multicenter clinical trial presented at the San Antonio Symposium.

GREENVILLE, NC—Patient age and surgeon experience appear to play the biggest role in failure of sentinel lymph node biopsy for detection of breast cancer, according to a large multicenter clinical trial presented at the San Antonio Symposium.

In a multivariate analysis of potential factors associated with biopsy failure, only patient age of 50 years or greater and a procedural experience of 10 or fewer cases correlated significantly with failure, said Peter Ng, MD, of East Carolina University.

“Our data also suggest that medial tumor location correlates with a higher false-negative rate, though the correlation was not statistically significant in our series,” Dr. Ng said.

Dr. Ng reported findings from the first prospective, randomized, multicenter trial that used both radiolabeled sulfur colloid and isosulfan blue dye to identify sentinel nodes. The study involved 485 patients and 41 surgeons. Three fourths of the patients had infiltrating ductal carcinoma, and 90% of the tumors were smaller than 5 cm. All sentinel node findings were confirmed by axillary node dissection.

“Participating surgeons were not required to have any prior experience with sentinel node biopsy outside of an initial training course,” Dr. Ng said. “No surgeon had participated in a learning trial of sentinel node biopsy prior to joining the study.”

The surgeons successfully identified the sentinel node in 420 of the 485 patients for an 87% success rate. In addition to the 65 patients with no sentinel node identified, there were 18 false-negative sentinel node biopsies (13%). A false-negative finding was defined as identification of a sentinel node that proved to be pathologically negative with a positive nonsentinel node identified by axillary dissection.

Correlation analysis of factors associated with biopsy success and failure included surgeon experience, probe type, primary tumor location, tumor size, method of tumor diagnosis (fine needle aspiration, core biopsy, previous lumpectomy, or previous biopsy), patient age, vascular lymphatic invasion, and dye injection interval.

Independent Predictors

Only patient age and surgeon experience proved to be significant independent predictors of sentinel node biopsy outcome. Mapping failure occurred in 5.1% of patients younger than 50, compared with 15.4% in patients 50 and older. Surgeons who performed more than 10 cases had a failure rate of 8.2%, compared with 17.9% for surgeons who had performed 10 or fewer cases.

Medial tumor location was a statistically significant predictor of biopsy success in a univariate analysis, but not in the multivariate analysis.

“On the basis of our results, we recommend that surgeons not abandon complete axillary node dissection without adequate sentinel node experience,” Dr. Ng concluded, “and that surgeons show discretion in applying this technique to older patients and those who have medial tumors.”

A Decrease in Lymphatics?

In answer to a question, Dr. Ng hypothesized that the failure rate in older women is due to anatomical changes that develop with age and fatty changes in the breast. “There’s probably a decrease in the lymphatics that in some way contributes to the increased failure rate,” he said.

When asked how many procedures are generally required to achieve an adequate success rate, Dr. Ng said he agreed with the consensus statement of the American College of Surgeons, which recommends 30 cases, with a success rate of greater than 85% and a false-negative rate of less than 5%.

Related Videos
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.
Experts on breast cancer
Experts on breast cancer
Experts on breast cancer
Related Content